Canertinib
Sign in to save this workspacePrimary targets: ERBB2_HER2 · FDA status: FDA Trials Discontinued
Selectivity scorecard
KISS
96.49
Gini
0.671
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Canertinib. Strongest target: TXK at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | TXK | 100.0% | 0.0% |
| 2 | BLK | 99.7% | 0.3% |
| 3 | ERBB4_HER4 | 99.6% | 0.4% |
| 4 | BMX_ETK | 99.4% | 0.6% |
| 5 | ERBB2_HER2 | 99.4% | 0.6% |
| 6 | BTK | 99.3% | 0.7% |
| 7 | JAK3 | 98.9% | 1.1% |
| 8 | DDR1 | 98.5% | 1.5% |
| 9 | EGFR | 98.4% | 1.6% |
| 10 | LCK | 97.7% | 2.3% |
| 11 | ITK | 96.9% | 3.1% |
| 12 | LYN | 95.2% | 4.8% |
| 13 | EPHA6 | 92.1% | 7.9% |
| 14 | ABL1 | 91.6% | 8.4% |
| 15 | RET | 88.0% | 12.1% |
| 16 | YES_YES1 | 87.8% | 12.2% |
| 17 | FGR | 87.3% | 12.7% |
| 18 | RIPK2 | 87.1% | 12.9% |
| 19 | MNK2 | 87.0% | 13.0% |
| 20 | EPHB4 | 86.9% | 13.1% |
Selectivity landscape
Where Canertinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Canertinib.
Annotations
Sign in to read and post annotations.
Loading…